XML 19 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2020
Cash Flows from Operating Activities      
Net loss $ (20,930) $ (23,998)  
Adjustments to reconcile net loss to net cash used in operating activities:      
Stock-based compensation 5,935 2,660  
Operating lease right-of-use asset amortization 584 444  
Net amortization of premium on marketable securities 358 348  
Depreciation 249 180  
Changes in operating assets and liabilities:      
Research and development tax incentive receivable   (751)  
Receivable from collaboration partner - related party (23,584) (1,570)  
Prepaid expenses and other assets 1,279 57  
Accounts payable 5,559 (344)  
Payable to collaboration partner - related party (519) 4,091  
Accrued expenses and other payables (5,110) (673)  
Deferred revenue - related party (833) (8,709)  
Operating lease liability (654) (491)  
Net cash used in operating activities (37,666) (28,756)  
Cash Flows from Investing Activities      
Purchase of marketable securities (55,832) (87,205)  
Proceeds from maturities of marketable securities 51,629 80,552  
Purchases of property and equipment (273) (140)  
Net cash used in investing activities (4,476) (6,793)  
Cash Flows from Financing Activities      
Proceeds from at-the-market offering, net of issuance costs 14,553    
Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan 2,558 1,316  
Tax withholding payments related to net settlement of restricted stock units (186) (189)  
Issuance costs related to common stock offering   (148)  
Net cash provided by financing activities 16,925 979  
Effect of exchange rate changes on cash, cash equivalents and restricted cash 29 (23)  
Net decrease in cash, cash equivalents and restricted cash (25,188) (34,593)  
Cash, cash equivalents and restricted cash, beginning of period 123,890 117,818  
Cash, cash equivalents and restricted cash, end of period 98,702 83,225 $ 117,818
Supplemental Disclosure of Non-Cash Financing and Investing Information:      
Purchases of property and equipment in accounts payable and accrued liabilities 235 97  
Public Offering | Accrued liabilities and other payables      
Supplemental Disclosure of Non-Cash Financing and Investing Information:      
Issuance costs related to common stock offering $ 25 $ 58 $ 205